Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that starting on March 15, 2021, its KOIOS™ nootropic beverage products will be sold in all 11 supermarket locations of Market of Choice, Inc. (“Market of Choice”), a chain of grocery stores in Oregon. With approximately 30 existing retailers of Koios beverages in Oregon (population 4.2 million), the addition of all five KOIOS™ flavours to the in-store offerings of Market of Choice in its 11 locations can further strengthen awareness and adoption of the Company’s products in the Oregon market. With approximately 135 stores also carrying Koios beverages in California and Washington State, this placement adds to the Company’s already strong presence on the west coast of the United States with a nationwide total of more than 4,000 stores that sell Koios products.
Market of Choice was founded in 1979 with a single location in Cottage Grove, Oregon under the name of Thriftway Market. After acquiring several other grocery stores which operated under the Price Chopper and PC Market banners, the Market of Choice identity was introduced in 2000 in response to demand from patrons for a greater selection of natural and organic products alongside conventional grocery offerings1. As of 2021, Market of Choice employs over 1,400 Oregonians and has locations in Ashland, Belmont, Bend, Cedar Mill, Corvallis, Delta Oaks, Franklin, Medford, West Linn, Willakenzie, and Willamette. Over 7,000 local products are sold at Market of Choice supermarkets in traditional grocery categories as well as homewares, beer and wine, and whole health2. In 2008 Market of Choice made local headlines for its decision to abandon plastic shopping bags at its checkouts, inspired by natural foods giant Whole Foods who also eliminated plastic bags from its stores in the United States, Canada, and the United Kingdom earlier in the same year3.
The Company’s extensive commercialization initiatives in 2019 and 2020 have created a robust infrastructure of both retailers and wholesale distributors of Koios’ beverage products. Additionally, the Company has established a pipeline of online sales through its own e-commerce portal (offering one-time purchase and subscription options), as well as through Walmart’s U.S. online grocery store, and through Amazon.com. Along with placements announced earlier this month in over 200 Colorado convenience stores, as well as placements in Good Earth Natural Foods (Utah’s largest purveyor of sports nutrition products), the Company has also secured regional distribution on the east coast of the United States through Chex Finer Foods, Inc., a major natural and specialty foods distributor in New England. The Company believes that placements with chains such as Market of Choice reflect confidence in Koios’ products from the Company’s distribution partners, as well as the management of stores and chains who continue to recognize the relevance of KOIOS™, Fit Soda™, and other Koios products to their respective customer bases.
Koios Chief Executive Officer Chris Miller commented, “Local grocery chains are a key player in our distribution strategy for our canned beverage products for the simple reason that they have unparalleled influence in the regional markets that they service, in addition to knowledge of local clientele. Even through our online sales, which we manage in-house, there are discernible and meaningful patterns from one part of the country to another in terms of interest levels and purchasing tendencies. As much as these patterns may be insightful when it comes to our strategies for entering a given market, we prefer to take a more personalized approach of working with local-level retailers to best align our products with their base of customers. After all, these regional chains are often family-owned and are usually intimately familiar with what their customers like, dislike, and are specifically asking for. As such, we are excited to be working with Market of Choice as we expand our presence in the state of Oregon with a local focus.”
On behalf of the Board of Directors of the Company,
KOIOS BEVERAGE CORP.
Chris Miller, CEO, and Director
For further information, please contact:
THE CANADIAN SECURITIES EXCHANGE (CSE) HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.
About Koios Beverage Corp.
The Company is an emerging functional beverage company which has an available distribution network of more than 4,400 retail locations across the United States in which to sell its products. Koios has relationships with some of the largest and most reputable distributors in the United States, including Europa Sports, Muscle Foods USA, KeHE, and Wishing-U-Well. Koios uses a proprietary blend of nootropics and natural organic compounds to enhance human productivity without using harmful chemicals or stimulants. Koios products have been shown to enhance focus, concentration, mental capacity, memory retention, cognitive function, alertness, brain capacity and create all day mental clarity. Its ingredients are specifically designed to target brain function by increasing blood flow, oxygen levels and neural connections in the brain.
Koios produces one of the only drinks in the world infused with MCT oil. MCT oil is derived from coconuts and has been shown to help the body burn fat more effectively, create lasting energy from a natural food source, produce ketones in the brain, allowing for greater brain function and clarity, support healthy hormone production and improve immunity. For more information, please visit our website: https://www.koiosbeveragecorp.com.
This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking information and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information in this news release includes statements regarding: Potential outcomes from the placement of the Company’s beverage products in Market of Choice supermarkets in Oregon. The forward-looking information reflects management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking information. Although the Company believes that the assumptions and factors used in preparing the forward-looking information are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. Factors that could cause actual results or events to differ materially from current expectations include: (i) adverse market conditions; (ii) changes to the growth and size of the functional beverage markets; and (iii) other factors beyond the control of the Company. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking information. The forward-looking information included in this news release are made as of the date of this news release and the Company expressly disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law.
The statements in this news release have not been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking the Company’s products will vary from person to person. No claims or guarantees can be made as to the effects of the Company’s products on an individual’s health and well-being. The Company’s products are not intended to diagnose, treat, cure, or prevent any disease.
This news release may contain trademarked names of third-party entities (or their respective offerings with trademarked names) typically in reference to (i) relationships had by Koios with such third-party entities as referred to in this release and/or (ii) client/vendor/service provider parties whose relationship with Koios is/are referred to in this release. All rights to such trademarks are reserved by their respective owners or licensees.
Emerging leader in health and wellness beverages and products, BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) (“BevCanna” or the “Company”) is pleased to announce that it has added glass manufacturing capabilities to its industry leading high-capacity beverage facility, creating the only full service manufacturing facility with the ability to produce PET, aluminum, and glass form factors, available in multiple sizes and custom shapes.
The Company also announces that is has entered into the following agreements:
- a marketing and investor relations agreement (the “Winning Agreement”) dated February 5, 2021 with Winning Media LLC (“Winning”) pursuant to which Winning has agreed to provide certain corporate branding, marketing, online corporate communications and investor relations services to the Company for a term of three months for total cash consideration of US$150,000, which was paid upon entry into the Winning Agreement. The Company and Winning maintain an arm’s length relationship, and Winning does not have any interest, directly or indirectly, in the securities of the Company;
- a marketing and investor relations agreement (the “Capital Agreement”) dated February 11, 2021 with XF Capital Holdings Corp. (“Capital”) pursuant to which Capital has agreed to provide certain corporate branding, marketing, online corporate communications and investor relations services to the Company for a term of two months for total cash consideration of US$40,000, which was paid upon entry into the Capital Agreement. The Company and Capital maintain an arm’s length relationship, and Capital does not have any interest, directly or indirectly, in the securities of the Company;
- a marketing and investor relations agreement (the “EMC Agreement”) dated February 12, 2021 with Emerging Markets Consulting, LLC (“EMC”) pursuant to which EMC has agreed to provide certain corporate branding, marketing, online corporate communications and investor relations services to the Company for a term of two months for total cash consideration of US$350,000, which was paid upon entry into the EMC Agreement. The Company and EMC maintain an arm’s length relationship, and EMC does not have any interest, directly or indirectly, in the securities of the Company;
- a marketing and investor relations agreement (the “Hybrid Agreement”) dated February 12, 2021 with Hybrid Financial Ltd. (“Hybrid”) pursuant to which Hybrid has agreed to provide certain corporate branding, marketing, online corporate communications and investor relations services to the Company for a term of six months for total cash consideration of $60,000, which will be paid monthly to Hybrid. The Company and Hybrid maintain an arm’s length relationship; and
- a marketing and investor relations agreement (the “TDR Agreement”) dated February 12, 2021 with The Dales Report Inc. (“TDR”) pursuant to which TDR has agreed to provide certain corporate branding, marketing, online corporate communications and investor relations services to the Company for a term of six months for total cash consideration of $60,000, which will be paid monthly to TDR. The Company and TDR maintain an arm’s length relationship and TDR does not have any interest, directly or indirectly, in the securities of the Company.
About BevCanna Enterprises Inc.
BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) develops and manufactures cannabinoid-infused beverages and consumer products for in-house brands and white label clients. With decades of experience creating, branding and distributing iconic brands that have resonated with consumers on a global scale, the team demonstrates an expertise unmatched in the emerging cannabis beverage category. Based in British Columbia, Canada, BevCanna owns the exclusive rights to a pristine spring water aquifer, access to a world-class 40,000-square-foot, HACCP certified manufacturing facility, with a current bottling capacity of up to 210M bottles per annum. BevCanna also recently acquired US natural health and wellness e-commerce platform Pure Therapy. BevCanna’s vision is to be a global leader in infused innovations.
On behalf of the Board of Directors:
John Campbell, Chief Financial Officer and Chief Strategy Officer
Director, BevCanna Enterprises Inc.
Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the “Company” or “Canntab“), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is thrilled to announce the Canadian Intellectual Property Office (“CIPO“) has allowed Canadian Patent No. CA 3050150 to Canntab, related to its proprietary cannabidiol formulations with a priority date of January 23, 2017. The term of the patent expires on January 22, 2038.
Canntab’s Legal Counsel on intellectual property, Gavin Bogle of Magyar, Bogle & O’Hara LLP said, “The allowance of Canntab’s patent by the Canadian Intellectual Property Office provides fundamental intellectual protection for Canntab’s innovative tableting technology and validates the years of research and development the company has conducted. The Company now has patent protection in Canada and the USA providing an international scope to the Company’s expanding portfolio of issued patents.”
Canntab believes its hard pill formulations are superior to all other medical CBD and THC delivery systems since they are true pharmaceutical grade delivery systems which provide for superior ingredient stability, enhanced bioavailability, and provide customizable and precise dosing, as opposed to the widely available gel caps and capsule products from other suppliers.
Larry Latowsky, CEO of Canntab said, “This is another major milestone that confirms our proprietary formulations are unique and differentiated from other product offerings in the global marketplace. Intellectual property is at the root of our value proposition and, having been granted our first Canadian patent and our second patent overall in less than 5 months, further confirms our leading position as the go to company for precise dosage and pharmaceutical grade tablets for the medical market containing THC, CBD or any combination of THC and CBD.” Mr. Latowsky added “we are particularly pleased with the opportunities that are being presented for us to provide solutions to the USA market with the anticipated regulatory changes contemplated by the Biden Administration which we anticipate will allow us faster access to the largest medical cannabis market in the world”.
To further advance our IP, Canntab intends to prove greater bio-availability through a blood level study at a third party Clinical Research Organization (“CRO”). This study is currently in the planning phase and Canntab will provide further details on timing and results as soon as this information becomes available. Going forward, Canntab is able to provide extended-release formulations, whether the intended use is for medical, recreational or nutraceutical purposes, which will make it easier for doctors, patients, and the average consumer to make Canntab products their preferred cannabinoid delivery option.
Canntab has filed more than a dozen patent applications in the United States and Canada for which two have now been granted or allowed. Canntab has developed both patented and patent pending technologies to deliver standardized medical cannabis extract from selective strains in a variety of extended-release/ sustained-release pharmaceutical grade delivery systems.
On September 21, 2020 Canntab had announced that pursuant to a filing made in March 2017, the U.S. Patent and Trademark Office (USPTO) had issued U.S. Patent No. 10,772,837 to Canntab, titled “Modified Release Multi-Layer Tablet Cannabinoid Formulations. The term of the patent expires on March 15, 2038. The patent granted was for Canntab’s bi-layer or multi-layer tablets consisting of both Instant Release (“IR”) and Extended Release (‘XR”) formulations with THC, CBD and a variety of Terpenes and other Cannabinoids found in full spectrum Cannabis and Hemp oil resin.
About Canntab Therapeutics
Canntab Therapeutics is a Canadian biopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. Long referred to as Cannabis 3.0 by the Company, Canntab’s proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in pharmacies around the world. These will include the following formulations: once a day and extended release, both providing an accurate dose and improved shelf stability.
Canntab holds a Cannabis Standard Processing & Sales for Medical Purposes License, a Cannabis Research License, and an Industrial Hemp License from Health Canada.
Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.
This press release contains forward-looking statements. Forward-looking statements are statements that contemplate activities, events or developments that the Company anticipates will or may occur in the future. Forward-looking statements in this press release include, but are not limited to, those regarding anticipated regulatory changes in the United States allowing the Company to access that market quicker than initially anticipated, and the Company being able to provide greater bio-availability through a blood level study at a third party Clinical Research Organization. The material factors or assumptions used to develop these forward-looking statements include that the federal administration in the United States will repeal legislation rendering the use and possession of cannabis illegal for any purpose, including medical purposes, and that the proposed blood level study at a third party Clinical Research Organization will demonstrate that the Company’s products have greater bioavailability than its competitors. Although the Company believes that the assumptions inherent in these forward-looking statements are reasonable, they are not guarantees of future performance and, accordingly, they should not be relied upon and there can be no assurance that any of them will prove to be accurate. These forward-looking statements reflect the Company’s current expectations based on information currently available to management and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those projected. Risks and uncertainties include, but are not limited to, the risk that the federal administration in the United States declines to repeal legislation rendering the use and possession of cannabis illegal for any purpose, including medical purposes, and that the study conducted by a third party Clinical Research Organization demonstrates that the Company’s products do not have greater bioavailability. Readers should refer to the risk disclosure included from time-to-time in the documents the Company files on SEDAR, available at www.sedar.com. Finally, these forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update them except as required by applicable law.
Redfund Capital Corp. (CSE:LOAN, Frankfurt:O3X4, OTCQB:PNNRF) (Redfund or the “Company”) is pleased to announce CannaForum BV “CANNA” our newest portfolio client, has been notified it remains in the last 40 cannabis applications and that over 100 other submissions have been rejected to date by the Dutch government in their Closed Cannabis Supply Chain Experiment.
Redfund previously announced on July 29 that the Company had signed a letter of intent with CannaForum BV a company registered in the Netherlands, that had submitted an application for a cannabis cultivation license to the Dutch government in a new experiment program for the legal cultivation of cannabis in the Netherlands. Redfund and CannaForum have begun discussing a definitive agreement and terms will be disclosed when appropriate. 10 Cannabis producers will be awarded licenses in early 2021 and will be the only companies allowed to legally operate from 2021 to at least 2025 in the Netherlands. The Dutch experiment includes 79 retailers / `Coffeeshops’ within 10 selected cities. All retailers in the experiment are required to purchase all their products from the 10 selected producers. According to the application submitted to the Netherlands government, a minimum of 65.000 kg is required to be produced by 10 producers on an annual basis to supply all 79 retailers. For each producer: 6.500 kg at current Dutch wholesale prices translates to approx. 12-20m revenues annually.
“Joint operation of the Dutch license is how we envision our participation with CannaForum. Our portfolio clients have been on calls with the Dutch team and we agree this will be a very strong strategic joint venture opportunity for both companies. The Redfund team with the consumer products expertise and manufacturing experience will help jumpstart CannaForum with additional SKUs if they receive a coveted license,” said Meris Kott, CEO. Corporate Update The board of directors has adopted an advance notice policy which includes, among other things, a provision that requires advance notice be given to the Company in circumstances where nominations of persons for election to the Board are made by shareholders of the Company other than pursuant to: (i) a requisition of a meeting made pursuant to the provisions of the Business Corporations Act (ii) a shareholder proposal made pursuant to the provisions of the Business Corporations Act. The advance notice policy sets a deadline by which holders of record of common shares of the Company must submit director nominations to the Company prior to any annual or special meeting of shareholders, sets forth the information that a shareholder must include in the notice to the Company, and establishes the form in which the shareholder must submit the notice for that notice to be in proper written form. In the case of an annual meeting of shareholders, notice to the Company must be made not less than 30 days nor more than 65 days prior to the date of the annual meeting.
However, in the event that the annual meeting is to be held on a date that is less than 40 days after the date on which the first public announcement of the date of the annual meeting was made, notice may be made not later than the close of business on the tenth (10th) day following such public announcement.
About Redfund Capital Corp.
Redfund partners with first mover, high growth companies, and provides them with access to capital, resources, and infrastructure. The present focus of the merchant bank is on global wellness, hemp and CBD-related, healthcare- related target companies.
For further information please visit www.redfundcapital.com
For more information on Redfund Capital Corp. contact Meris Kott CEO 604.484.0355 or firstname.lastname@example.org
Further information about the Company is available on www.SEDAR.com under the Company’s profile.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this release may constitute “forward looking statements” or “forward-looking information” (collectively “forward-looking information”) as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “anticipates” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, the Property, financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
FSD Pharma Inc. (formerly, Century Financial Capital Group Inc., the “Corporation”) is pleased to announce that it has completed its previously announced business combination with FV Pharma Inc. (“FV Pharma”). On March 9, 2018 the Corporation and FV Pharma entered into an arm’s length definitive business combination agreement (the “Business Combination Agreement”) with 2620756 Ontario Inc. (“SubCo”), a wholly-owned subsidiary of the Corporation, incorporated for the purpose of this transaction. Pursuant to the Business Combination Agreement, the Corporation changed its name to FSD Pharma Inc. and completed a business combination with FV Pharma by way of a three-cornered amalgamation pursuant to which FV Pharma amalgamated with SubCo (the “Transaction”). The resulting amalgamated corporation carried on in the name of FV Pharma as a wholly-owned subsidiary of the Corporation. Following the completion of the Transaction, FSD Pharma Inc. will carry on the medical cannabis business of FV Pharma. For the purposes of this press release, the term “Resulting Issuer” means the Corporation following completion of the Transaction.
On March 15, 2018, the Corporation held an annual and special meeting of the shareholders of the Corporation (the “Shareholders”), where the Shareholders approved a share re-designation, a name change, and other matters relating to the Transaction.
In connection with the Transaction, the Shareholders passed a special resolution authorizing the Corporation’s board of directors to amend the Corporation’s articles in order to: (i): effect a re-designation of the Corporation’s existing common shares as Class B Subordinate Voting Shares (the “Class B Subordinate Voting Shares”) (ii) create a new class of “Class A Multiple Voting Shares” and (iii) eliminate the existing classes of non-voting “Class A Preference Shares” and non-voting “Class B Preference Shares”
In connection with the Transaction, the Shareholders passed a special resolution authorizing the Corporation’s board of directors to amend the articles of incorporation of the Corporation to effect the change of name of the Corporation to “FSD Pharma Inc.”
Board of Directors
The Corporation’s new board of directors following the transaction is constituted by Thomas Fairfull, Zeeshan Saeed, Donal Carroll, Vladimir Klacar and Gerald Goldberg.
Further to a previously announced two-tranche private placement of subscription receipts (“Subscription Receipts”) of FV Pharma for gross proceeds of approximately $33,404,392 (the “Financing”), FV Pharma is pleased to announced that it has satisfied the escrow release conditions set out in the agency agreement dated March 9, 2018 between FV Pharma, the Corporation and First Republic Capital Corporation (the “Agent”) and the subscription receipt agreement dated March 9, 2018 among FV Pharma, the Agent and Garfinkle Biderman LLP, as subscription agent, and that the net proceeds ($29,862,645) have been released to the Corporation.
The Resulting Issuer’s securities are not currently listed on any stock exchange. The Resulting Issuer has applied to list its Class B Subordinate Voting Shares on the Canadian Securities Exchange (the “CSE”), and conditional approval to list the Class B Subordinate Voting Shares has been granted. The Corporation is anticipating that the Class B Subordinate Voting Shares will commence trading on the CSE on or about May 29, 2018 under the ticker symbol “HUGE”. There is no assurance that the Resulting Issuer will ultimately be able to satisfy the listing requirements of the CSE.
About FSD Pharma Inc.
FSD Pharma, owns, through its wholly-owned subsidiary FV Pharma Inc., a license to produce marijuana under the Access to Cannabis for Medical Purposes Regulations (ACMPR) which was originally granted on October 13, 2017. Headquartered at the former Kraft plant in Cobourg, Ontario, approximately an hour’s drive from Toronto, FSD Pharma’s management’s mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world. FSD Pharma intends to target all legal aspects of the cannabis industry, including cultivation, processing, manufacturing, extracts and research and development. To date FSD Pharma and FV Pharma have raised over $53 million from over 4,700 shareholders.
Bennett Jones LLP, McMillan LLP and Garfinkle Biderman LLP acted for FV Pharma, Century Financial Capital Group Inc. and the Agent, respectively, in connection with the Transaction.
For further information please contact:
Chief Executive Director, FSD Pharma Inc.
Investor Relations, FSD Pharma Inc.
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the Transaction, including the listing and trading of the Corporation’s Class B Subordinate Voting Shares on the CSE, changes to laws and compliance with applicable regulations. The forward-looking information contained in this press release is made as of the date hereof, and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking-information. The foregoing statements expressly qualify any forward-looking information contained herein.
Naturally Splendid Enterprises Ltd. (“Naturally Splendid”, “NSE” or “the Company”) (FRANKFURT:50N) (TSXV:NSP) (OTC:NSPDF) is pleased to announce that Naturally Splendid Director and President of the Canadian Hemp Trade Alliance (CHTA), Mr. Russ Crawford, was a key speaker at the recent Senate hearing on May 23rd, 2018, to review hemp and its inclusion under Bill C-45 the Cannabis Act.
Representing the CHTA, Mr. Crawford acknowledged the fine work of the Marijuana Task Force in developing Proposed Regulations for the new Act which include important changes and reduced regulation for the production, processing and commercial sale of industrial hemp. The CHTA spoke in favour of Senate support for Bill C-45 which will provide a less regulated commercial environment for the hemp industry in Canada.
Two key points were made by Mr. Crawford. Firstly, the removal of hemp and its derivatives from the list of Controlled Substances, an unnecessary and inaccurate characterization of hemp which has created public misconception and stigmatized reluctance to consumption. Secondly, the expansion of opportunity in the hemp industry in the form of “whole plant use”. Passage of the Bill will enable hemp farmers, processors and scientists to conduct research and product development on the full spectrum of cannabinoids present in the leaves and flowers of the plant adding to the current crop value of seed and fibre.
“The hemp industry still has a lot of work to do in the development of food, fibre, feed and natural health product markets and this legislation opens the door for all stakeholders”, stated Crawford. “Similar to the establishment of the enabling legislation of the Industrial Hemp Regulations Act in 1997, passing this Bill restates Canada’s global leadership in the industrial hemp market.”
The sale of hemp products from Canada has grown from zero in 1997 to $180 million in 2017. Passage of this Bill would be viewed as a positive statement to investors and consumers inviting an influx of capital expansion to the hemp sector. The CHTA forecasts total sales could reach $1 billion by 2023.
Naturally Splendid is well positioned to act on this pending legislation by adding new, formulated products that include cannabinoids in the areas of human food, cosmetics, health and wellness products and pet foods and health treatments. Bryan Carson, Naturally Splendid’s Executive V.P. of Innovation & Marketing, adds, “We have been hard at work developing formulations and specific targeted products which will contain cannabinoids derived from hemp. This is a new and exciting opportunity for our company to achieve our goals in the creation of nutritious functional foods made from hemp.”
About Naturally Splendid Enterprises Ltd.
Naturally Splendid is a biotechnology and consumer products company that is developing, producing, commercializing, and licensing an entirely new generation of plant-derived, bioactive ingredients, nutrient dense foods, and related products. Naturally Splendid is building an expanding portfolio of patents (issued and pending) and proprietary intellectual property focused on the commercial uses of industrial hemp and non-psychoactive cannabinoid compounds in a broad spectrum of applications.
Naturally Splendid currently has four innovative divisions:
(1)BIOTECHNOLOGY – Focused on three major platforms:
i.Proprietary HempOmega(TM) encapsulation
ii.Extraction and formulation with Cannabidiol (CBD)
iii.Hemp and plant-based proteins.
(2) CONSUMER PRODUCTS –
– NATERA(R) – brand of retail hemp and superfood products distributed throughout North America, Asia and Europe.
– Prosnack Natural Foods Inc. (Elevate Me(TM)) – lifestyle brand of healthy meal replacement products distributed throughout North America.
– Chi Hemp Industries Incorporated (CHII) – e-commerce platform for natural and organic hemp products.
– PawsitiveFX(R) – topical pet care products.
– NATERA(R)CBD – retail hemp-based cannabinoid nutraceutical and cosmeceutical products distributed in Asia.
– NATERA(R)Skincare – brand of retail hemp based cosmeceutical products.
(3) NATERA(R) Ingredients – bulk ingredients including HempOmega(TM).
(4) Co-Packaging/Toll-Processing – packaging for house-brands (NATERA(R) and CHII) and third-party partners.
For more information e-mail email@example.com or call Investor Relations at 604-673-9573
On Behalf of the Board of Directors
Mr. Douglas Mason
Naturally Splendid Enterprises Ltd.
(NSP – TSX Venture; NSPDF – OTCQB; 50N Frankfurt)
#108-19100 Airport Way
Pitt Meadows, BC, V3Y 0E2
Office: (604) 465-0548
Fax: (604) 465-1128
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid’s control including, Naturally Splendid’s ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; the ability to complete the sales of all bulk hemp seed purchase orders; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.
NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.